• AbbVie flagged new Crohn’s disease results for SKYRIZI from its Phase 3 AFFIRM study, set for presentation at ACG 2026.
• AFFIRM showed patients on subcutaneous SKYRIZI achieved better disease control than placebo, with benefits holding through maintenance follow-up.
• Separate extension analyses to be shown at the meeting indicate SKYRIZI can sustain long-term bowel healing in harder-to-treat patients.
• Real-world studies scheduled for ACG also point to disease control with RINVOQ in advanced Crohn’s disease, including complex fistulizing cases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610111300PR_NEWS_USPR_____CG67599) on October 11, 2026, and is solely responsible for the information contained therein.